ARTICLE | Company News
NanoBio deal
August 8, 2011 7:00 AM UTC
NanoBio received exclusive, worldwide rights from NIH to an antigen against respiratory syncytial virus (RSV). NanoBio said it will combine its NanoStat adjuvant technology with the antigen for use in...